Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting-Reference-Cited by-同舟云学术

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting

Published:2021-12-17 Issue:1 Volume:6 Page:29-35
ISSN:2397-9070
Container-title:JGH Open
language:en
Short-container-title:JGH Open

Author:

Fukushima Taito¹²,Morimoto Manabu¹^ORCID,Ueno Makoto¹,Kubota Kousuke³,Uojima Haruki³^ORCID,Hidaka Hisashi³,Chuma Makoto⁴,Numata Kazushi⁴,Tsuruya Kota⁵,Hirose Shunji⁵,Kagawa Tatehiro⁵,Hattori Nobuhiro⁶,Watanabe Tsunamasa⁶^ORCID,Matsunaga Kotaro⁷,Yamamoto Kouji⁸,Tanaka Katsuaki⁹,Maeda Shin²

Affiliation:

1. Hepatobiliary and Pancreatic Oncology Kanagawa Cancer Center Yokohama Kanagawa Japan

2. Department of Gastroenterology Yokohama City University Graduate School of Medicine Yokohama Kanagawa Japan

3. Department of Gastroenterology, Internal Medicine Kitasato University School of Medicine Sagamihara Kanagawa Japan

4. Gastroenterological Center Yokohama City University Medical Center Yokohama Kanagawa Japan

5. Division of Gastroenterology and Hepatology, Department of Internal Medicine Tokai University School of Medicine Isehara Kanagawa Japan

6. Division of Gastroenterology and Hepatology, Department of Internal Medicine St. Marianna University School of Medicine Kawasaki Kanagawa Japan

7. Division of Gastroenterology and Hepatology Kawasaki Municipal Tama Hospital Kawasaki Kanagawa Japan

8. Department of Biostatistics, School of Medicine Yokohama City University Yokohama Kanagawa Japan

9. Gastroenterology Division Hadano Red Cross Hospital Hadano Kanagawa Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12691

Reference31 articles.

1. Hepatocellular carcinoma

2. Randomized controlled trial of screening for hepatocellular carcinoma

3. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort

4. Sorafenib in Advanced Hepatocellular Carcinoma

5. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study;European Journal of Gastroenterology & Hepatology;2024-01

2. Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis;JGH Open;2023-12

3. Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis;Medicine;2023-06-09

4. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population;European Journal of Cancer;2023-02

5. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis;Frontiers in Oncology;2022-12-22